Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Zynerba Pharmaceuticals (NASDAQ:ZYNE – Free Report) in a research note released on Saturday morning. The firm issued a sell rating on the stock. A number of other research firms have also issued reports on ZYNE. LADENBURG THALM/SH SH lowered shares of Zynerba Pharmaceuticals from a buy rating to a […]

Related Keywords

,Vident Investment Advisory ,Zynerba Pharmaceuticals Inc ,Millennium Management ,Renaissance Technologies ,Dimensional Fund Advisors ,Zynerba Pharmaceuticals ,Zynerba Pharmaceuticals Stock Performance ,Institutional Investors Weigh In On Zynerba Pharmaceuticals ,Vanguard Group Inc ,Canaccord Genuity Group ,News Ratings For Zynerba Pharmaceuticals Daily ,Free Report ,Fund Advisors ,Investment Advisory ,Get Free Report ,Zynerba Pharmaceuticals Daily ,Nasdaq Zyne ,Zyne ,Medical ,Initiated Coverage ,Stocknews Com ,